X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Journal Article (4045) 4045
Book Review (837) 837
Publication (195) 195
Magazine Article (33) 33
Conference Proceeding (28) 28
Newsletter (14) 14
Book / eBook (12) 12
Book Chapter (7) 7
Newspaper Article (4) 4
Trade Publication Article (4) 4
Paper (1) 1
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
index medicus (3367) 3367
humans (3127) 3127
male (1838) 1838
female (1685) 1685
quinolones - therapeutic use (1486) 1486
quinolones - adverse effects (1389) 1389
adult (1302) 1302
pharmacology & pharmacy (1143) 1143
middle aged (1115) 1115
aripiprazole (1061) 1061
quinolones (1055) 1055
piperazines - therapeutic use (775) 775
quinolones - administration & dosage (747) 747
antipsychotic agents - adverse effects (746) 746
piperazines - adverse effects (746) 746
aged (739) 739
antipsychotic agents - therapeutic use (726) 726
fluoroquinolones (711) 711
treatment outcome (709) 709
animals (702) 702
psychiatry (695) 695
quinolones - pharmacology (544) 544
adolescent (536) 536
ciprofloxacin (523) 523
drug therapy (507) 507
double-blind (425) 425
antibiotics (412) 412
schizophrenia (407) 407
double-blind method (404) 404
schizophrenia - drug therapy (403) 403
dose-response relationship, drug (385) 385
drug therapy, combination (366) 366
quinolone antibacterial agents (366) 366
abridged index medicus (350) 350
infectious diseases (336) 336
safety (324) 324
efficacy (321) 321
anti-infective agents - adverse effects (320) 320
dosage and administration (312) 312
microbiology (300) 300
anti-infective agents - therapeutic use (289) 289
pharmacokinetics (282) 282
young adult (281) 281
child (280) 280
quinolones - pharmacokinetics (278) 278
analysis (273) 273
research (273) 273
piperazines - administration & dosage (271) 271
care and treatment (270) 270
risk factors (262) 262
aged, 80 and over (259) 259
medicine & public health (259) 259
administration, oral (257) 257
anti-bacterial agents - therapeutic use (253) 253
clinical neurology (252) 252
medicine, general & internal (247) 247
drug administration schedule (245) 245
anti-bacterial agents - adverse effects (240) 240
health aspects (240) 240
antipsychotic agents - administration & dosage (237) 237
levofloxacin (233) 233
neurosciences (226) 226
rats (225) 225
drug interactions (222) 222
internal medicine (211) 211
clinical trials (207) 207
quinolone (207) 207
respiratory system (207) 207
time factors (203) 203
complications and side effects (202) 202
toxicology (198) 198
microbial sensitivity tests (196) 196
oncology (196) 196
therapy (194) 194
drugs (193) 193
mice (191) 191
pharmacology/toxicology (183) 183
olanzapine (175) 175
pharmacology (174) 174
infections (173) 173
ofloxacin (173) 173
prospective studies (170) 170
risperidone (170) 170
randomized controlled trials as topic (167) 167
anti-bacterial agents - pharmacology (166) 166
immunology (165) 165
anti-infective agents - pharmacology (161) 161
drug resistance (156) 156
placebo (156) 156
pulmonary disease, chronic obstructive - drug therapy (156) 156
pharmacotherapy (155) 155
bipolar disorder - drug therapy (153) 153
psychiatric status rating scales (153) 153
atypical antipsychotics (150) 150
anti-infective agents - administration & dosage (147) 147
children (144) 144
retrospective studies (142) 142
clinical trials as topic (141) 141
usage (141) 141
psychotic disorders - drug therapy (140) 140
more...
Library Location Library Location
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (3943) 3943
Japanese (41) 41
French (37) 37
German (27) 27
Spanish (21) 21
Russian (10) 10
Dutch (7) 7
Chinese (6) 6
Portuguese (4) 4
Swedish (4) 4
Hungarian (3) 3
Italian (3) 3
Czech (2) 2
Danish (2) 2
Korean (2) 2
Bulgarian (1) 1
Norwegian (1) 1
Polish (1) 1
Turkish (1) 1
Ukrainian (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Lancet, The, ISSN 0140-6736, 2015, Volume 385, Issue 9987, pp. 2606 - 2615
Summary Background Tenofovir disoproxil fumarate can cause renal and bone toxic effects related to high plasma tenofovir concentrations. Tenofovir alafenamide... 
Internal Medicine | KIDNEY-DISEASE | RATES | MEDICINE, GENERAL & INTERNAL | ABACAVIR-LAMIVUDINE | BONE-MINERAL DENSITY | SAFETY | ADULTS | ANTIRETROVIRAL THERAPY | LOPINAVIR/RITONAVIR | COUNT | EXPOSURE | Humans | Male | Thiazoles - administration & dosage | Carbamates - administration & dosage | Arthralgia - chemically induced | Thiazoles - adverse effects | Sleep Initiation and Maintenance Disorders - chemically induced | Tenofovir | Adenine - adverse effects | Quinolones - adverse effects | Adult | Anti-HIV Agents - therapeutic use | Deoxycytidine - adverse effects | Female | Headache - chemically induced | Emtricitabine | Adenine - analogs & derivatives | Kidney - drug effects | Respiration Disorders - chemically induced | Double-Blind Method | Anti-HIV Agents - adverse effects | Deoxycytidine - administration & dosage | HIV Infections - virology | Organophosphonates - adverse effects | Treatment Outcome | CD4 Lymphocyte Count | Nausea | Adenine - administration & dosage | Organophosphonates - administration & dosage | Bone Density - drug effects | Quinolones - administration & dosage | Carbamates - adverse effects | HIV Infections - drug therapy | Viral Load - drug effects | Cobicistat | Deoxycytidine - analogs & derivatives | Drug Combinations | Medical colleges | Clinical trials | Cross infection | Nosocomial infections | HIV (Viruses) | Drug therapy | Health aspects | HIV infection | Analysis | Antiretroviral drugs | Infections | Acquired immune deficiency syndrome--AIDS | Human immunodeficiency virus--HIV | Index Medicus | Abridged Index Medicus
Journal Article
Lancet Infectious Diseases, The, ISSN 1473-3099, 2014, Volume 14, Issue 7, pp. 581 - 589
Journal Article
JAMA: The Journal of the American Medical Association, ISSN 0098-7484, 10/2009, Volume 302, Issue 16, pp. 1765 - 1773
Journal Article
Journal Article
The New England Journal of Medicine, ISSN 0028-4793, 10/2018, Volume 379, Issue 17, pp. 1599 - 1611
This companion article to the VX-445 report shows that VX-659, a new CFTR potentiator, when administered with tezacaftor and ivacaftor improved lung function,... 
G551D MUTATION | MEDICINE, GENERAL & INTERNAL | IN-VITRO | CFTR POTENTIATOR | TEZACAFTOR-IVACAFTOR | Pyrazoles - therapeutic use | Forced Expiratory Volume - drug effects | Humans | Pyrrolidines - adverse effects | Chloride Channel Agonists - therapeutic use | Male | Aminophenols - therapeutic use | Chloride Channel Agonists - adverse effects | Aminophenols - adverse effects | Pyrrolidines - pharmacology | Pyrrolidines - therapeutic use | Sweat - chemistry | Young Adult | Quinolones - adverse effects | Quinolones - therapeutic use | Adult | Benzodioxoles - adverse effects | Female | Benzodioxoles - therapeutic use | Pyrazoles - adverse effects | Pyrazoles - pharmacology | Double-Blind Method | Cells, Cultured | Genotype | Cystic Fibrosis Transmembrane Conductance Regulator - metabolism | Chlorides - analysis | Indoles - adverse effects | Cystic Fibrosis - genetics | Adolescent | Alleles | Cystic Fibrosis Transmembrane Conductance Regulator - genetics | Indoles - therapeutic use | Mutation | Cystic Fibrosis - drug therapy | Drug Combinations | Cystic fibrosis | Ivacaftor | Genetic aspects | Dosage and administration | Drug therapy | Epithelial cells | Chloride transport | Clinical trials | Recovery of function | Patients | Proteins | Genotype & phenotype | Fibrosis | Conductance | Full text | Cystic fibrosis transmembrane conductance regulator | Protein transport | Sweat | Binding sites | Genotypes | Index Medicus | Abridged Index Medicus
Journal Article
The New England Journal of Medicine, ISSN 0028-4793, 07/2015, Volume 373, Issue 3, pp. 220 - 231
Journal Article
Journal of Clinical Psychopharmacology, ISSN 0271-0749, 04/2008, Volume 28, Issue 2, pp. 156 - 165
Journal Article
JAIDS Journal of Acquired Immune Deficiency Syndromes, ISSN 1525-4135, 05/2013, Volume 63, Issue 1, pp. 96 - 100
We report week 96 results from a phase 3 trial of elvitegravir/cobicistat/emtricitabine/tenofovir disoproxil fumarate (EVG/COBI/FTC/TDF, n = 348) vs... 
HIV | cobicistat | phase 3 randomized trial | safety | efficacy | stribild | INFECTIOUS DISEASES | CO-FORMULATED ELVITEGRAVIR | NON-INFERIORITY TRIAL | PHASE-3 | IMMUNOLOGY | TREATMENT-NAIVE | EFAVIRENZ | LOPINAVIR/RITONAVIR | TENOFOVIR | RITONAVIR | Efavirenz, Emtricitabine, Tenofovir Disoproxil Fumarate Drug Combination | Humans | Elvitegravir, Cobicistat, Emtricitabine, Tenofovir Disoproxil Fumarate Drug Combination | Male | RNA, Viral - blood | Thiazoles - administration & dosage | Carbamates - administration & dosage | Thiazoles - therapeutic use | Thiazoles - adverse effects | Young Adult | Deoxycytidine - therapeutic use | Adenine - adverse effects | HIV-1 - physiology | Quinolones - adverse effects | Adenine - therapeutic use | Quinolones - therapeutic use | Adult | Anti-HIV Agents - therapeutic use | Deoxycytidine - adverse effects | Female | Adenine - analogs & derivatives | Double-Blind Method | Organophosphonates - therapeutic use | HIV-1 - drug effects | Anti-HIV Agents - adverse effects | Deoxycytidine - administration & dosage | HIV Infections - virology | Organophosphonates - adverse effects | Treatment Outcome | Adenine - administration & dosage | Oxazines - adverse effects | Organophosphonates - administration & dosage | Quinolones - administration & dosage | Oxazines - therapeutic use | Creatinine - blood | Carbamates - adverse effects | HIV Infections - drug therapy | Carbamates - therapeutic use | Deoxycytidine - analogs & derivatives | Drug Combinations | Clinical trials | Patient safety | Immunology | Comparative analysis | Drug therapy | Human immunodeficiency virus--HIV | Indexing in process | Index Medicus | AIDS/HIV
Journal Article
The New England Journal of Medicine, ISSN 0028-4793, 06/2016, Volume 374, Issue 23, pp. 2222 - 2234
Journal Article